UNSPECIFIED (2002) Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer. In: Satellite Symposium on Gemcitabine and Targeted Therapies in Thoracic Cancer held in Conjunction with the European Conference on Perspectives in Lung Cancer, LONDON, ENGLAND, DEC, 2001. Published in: LUNG CANCER, 38 (Suppl. 2). S21-S28. ISSN 0169-5002.

Research output not available from this repository, contact author.

Request Changes to record.

Abstract

The introduction of any new chemotherapy agent for non-small cell lung cancer (NSCLC) ought to be considered carefully in light of both costs and measurable benefits. Decision making is straightforward if a new treatment is relatively cheaper and more effective (i.e. introduce new therapy) or more expensive and less effective (i.e. reject new treatment) than standard therapies. However, if a treatment is more expensive and also more effective, or less expensive but also less effective, decision making becomes more complicated. An economic evaluation of the cost-effectiveness of gemcitabine in advanced NSCLC was performed as a case study. A comprehensive literature search for published economic evaluations of gemcitabine was carried out. Economic studies examining treatment for advanced NSCLC were limited to cost-minimization analyses and cost-effectiveness analyses. The analyses included primary economic studies, e.g. trials that included an integral economic evaluation, and secondary research, e.g. analyses based on published trial data and modeling. Overall, gemcitabine regimens proved cost-effective against standard therapies in this analysis. Prospective economic and quality-of-life analyses should be incorporated into study designs to help identify treatments that will maximize societal health benefits. (C) 2002 Published by Elsevier Science Ireland Ltd.

Item Type:	Conference Item (UNSPECIFIED)
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RC Internal medicine
Journal or Publication Title:	LUNG CANCER
Publisher:	ELSEVIER SCI IRELAND LTD
ISSN:	0169-5002
Official Date:	November 2002
Dates:	Date Event November 2002 UNSPECIFIED
Volume:	38
Number:	Suppl. 2
Number of Pages:	8
Page Range:	S21-S28
Publication Status:	Published
Title of Event:	Satellite Symposium on Gemcitabine and Targeted Therapies in Thoracic Cancer held in Conjunction with the European Conference on Perspectives in Lung Cancer
Location of Event:	LONDON, ENGLAND
Date(s) of Event:	DEC, 2001

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item